RPRX
Royalty Pharma plc · Healthcare · Medical - Pharmaceuticals
Momentum inputs (comparable managers):
holder breadth +14.3% ·
share flow +6.6% ·
net new positions +12.5%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 146 | 0 | 306.62M | $17.19B | +5 | −4 |
| Q1 2026 | 148 | +6 | 297.67M | $14.26B | +10 | −5 |
| Q4 2025 | 141 | +1 | 305.31M | $11.80B | +2 | — |
| Q3 2025 | 19 | +1 | 173.40M | $6.12B | +2 | −2 |
| Q2 2025 | 16 | 0 | 158.26M | $5.71B | — | — |
| Q1 2025 | 13 | -3 | 61.13M | $1.91B | — | −3 |
| Q4 2024 | 16 | +2 | 77.30M | $1.97B | +2 | — |
| Q3 2024 | 13 | -1 | 62.78M | $1.78B | +1 | −2 |
| Q2 2024 | 14 | — | 58.59M | $1.54B | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Adage Capital Partners ✦ | 16.97M | +42.6% | $432.86M | 0.8% | ▲ Add | 3 | SEC ↗ |
| 2 | Baillie Gifford ✦ | 14.13M | -12.3% | $360.57M | 0.3% | ▼ Trim | 3 | SEC ↗ |
| 3 | Baillie Gifford ✦ | 14.13M | -12.3% | $360.57M | 0.3% | ▼ Trim | 3 | SEC ↗ |
| 4 | Baillie Gifford ✦ | 14.13M | -12.3% | $360.57M | 0.3% | ▼ Trim | 3 | SEC ↗ |
| 5 | Baillie Gifford ✦ | 14.13M | -12.3% | $360.57M | 0.3% | ▼ Trim | 3 | SEC ↗ |
| 6 | Viking Global Investors ✦ | 12.21M | +0.9% | $311.42M | 1.0% | ▲ Add | 3 | SEC ↗ |
| 7 | State Street Global Advisors ✦ (passive) | 9.76M | — | $248.95M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Geode Capital Management ✦ (passive) | 7.31M | +0.6% | $186.85M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 9 | Geode Capital Management ✦ (passive) | 7.31M | +0.6% | $186.85M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | Norges Bank ✦ (passive) | 4.88M | +1.5% | $124.50M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 11 | Citadel Advisors ✦ | 2.90M | New | $73.93M | 0.1% | New | 1 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 2.90M | New | $73.93M | 0.1% | New | 1 | SEC ↗ |
| 13 | Two Sigma Investments ✦ | 2.42M | -0.4% | $61.74M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 14 | Millennium Management ✦ | 2.42M | -44.4% | $61.61M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 1.90M | +187.0% | $48.56M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 1.90M | +187.0% | $48.56M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 1.90M | +187.0% | $48.56M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 18 | AQR Capital Management ✦ | 1.90M | +187.0% | $48.56M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 19 | AQR Capital Management ✦ | 1.90M | +187.0% | $48.56M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 20 | AQR Capital Management ✦ | 1.90M | +187.0% | $48.56M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 21 | D. E. Shaw & Co. ✦ | 1.16M | +24.6% | $29.62M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 22 | Arrowstreet Capital ✦ | 669.88K | -51.8% | $17.09M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 23 | Point72 Asset Management ✦ | 249.00K | -52.7% | $6.35M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 24 | T. Rowe Price ✦ | 246.45K | -13.9% | $6.29M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 25 | Bridgewater Associates ✦ | 49.42K | New | $1.26M | 0.0% | New | 1 | SEC ↗ |
| 26 | Wellington Management ✦ | 18.54K | +4.1% | $472,931 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 27 | Wellington Management ✦ | 18.54K | +4.1% | $472,931 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 28 | Wellington Management ✦ | 18.54K | +4.1% | $472,931 | 0.0% | ▲ Add | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Citadel Advisors | $73.93M | 0.1% |
| Citadel Advisors | $73.93M | 0.1% |
| Bridgewater Associates | $1.26M | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 583 holders, 354.58M shares, $16.55B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 100.00K sh · $6.00M
Officer · 9.23K sh · $540,752
Officer · 1.77K sh · $104,799
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
18.7% of class · View original SEC filing ↗
4.8% of class · View original SEC filing ↗